Introduction
The large family of human papillomaviruses (HPVs) comprises over 200 types of strains [1] , some of which having developed different strategies to persist in the population. They are responsible for benign diseases like anogenital and other mucocutaneous warts or recurrent respiratory papillomatosis, and also for various malignancies including the majority of cervical cancers, most anal cancers, around half of head and neck cancers [2] [3] [4] as well as vulvar (around 40%), vaginal (around 70%) and penile (around 50%) cancers [1] , causing significant morbidity in general population [5, 6] . Even after identifying the viral proteins necessary for the genome replication and partitioning (E1 and E2 proteins) or for the cell proliferation and apoptotic inhibition (E6 and E7 proteins), it still lacks an effective intra-body antiviral treatment [6] . At the moment, there are no antiviral agents for the treatment of genital HPV infections, so the management of HPV infection is oriented towards the lesions associated with the active infection, the ablative strategies deployed today having a great percentage of recurrences [2, 6] . Several studies aimed to demonstrate the effectiveness of one herbal medicinal product containing an aqueous ethanolic extract of a mixture of Echinacea purpurea, Echinacea pallida, Baptisia tinctoria and Thuja occidentalis (EBT) in viral infections, such as hepatitis B, HIV or respiratory tract infections [7] [8] [9] . We conducted an observational study in which we used this extract in women with cervical HPV positive tests in order to evaluate whether the immunological enhancer property of the extract helps the host's immune system to purge the virus from the cervix.
Materials and Methods

Study design
During 2015 -2016, we conducted a prospective multicentre observational study in female patients carrying HPV cervical strains. The study protocol was approved by the Ethics Committee of "Nicolae Malaxa" Clinical Hospital, Bucharest, Romania. Data was collected and processed by the authors. The inclusion criteria were: adult female patients (18 years or older) tested positive for HPV cervical strains with normal/abnormal Pap (Papanicolau) smear results that did not impose immediate cervical resection. Exclusion criteria: prior antiviral or surgical treatment for cervical HPV infection, current treatment with other immuno-stimulatory agents, pregnancy/nursing patients, high-grade cervical dysplasia on Pap smear. Upon enrolment, all patients signed a written informed consent and answered to the questions included in the enrolment protocol about the onset of sexual life, the number of sexual partners and sexual habits. At the first visit, all patients were screened for genital warts, anorectal warts and laryngeal papilloma by a mixed team of gynaecologists and otorhinolaryngologists. Colposcopy was offered to all patients with abnormal Pap smear in order to detect dysplastic cervical lesion suited for resection. Each patient received 9 tablets of EBT per day during three months with one month pause before repeating the therapy for another three months. One tablet of EBT contained 0.215 mL alcoholic extract (1:11) that equals to Baptisia tinctoria root/Echinacea root and Thuja occidentalis herba at a ratio of 5/3.75/1.
The extraction medium was ethanol 30% (v/v). After one year upon enrolment, the patients were tested for HPV cervical strains, the results being compared with the initial findings. They were asked to fill a patients' satisfaction form regarding the compliance to the treatment (duration, mode of administration, side effects). All patients were deferred to become pregnant during the study period.
Statistical analysis
The results are presented as numbers and frequencies for the qualitative variables and as averages and standard deviations for the quantitative variables. We tested the difference between proportion using Chi-square test and Fisher exact test. The one-sample Chi-square test and one-sample binomial test were used to assess the distribution of categorical and dichotomous variables. The statistical significance was set at p < 0.05. Statistical analysis was performed using the software SPSS 23.0.
Results and Discussion
A total of 104 patients were enrolled in our study. Out of the 104 randomized patients, 92 completed the trial. Seven of them did not report to the three months visit to receive the second dose of EBT and five of them stopped taking the study medication before completing the study (lack of compliance). No major adverse event had been reported during the study. Patient characteristics are presented in Table I . The mean age was 32.1 ± 7.1 years (range: 19 -51 years). 92.4% were from urban area and 53.3% were married. (Table II) . After completing the study, 27 (29.3%) patients had significant improvement demonstrated by the results of the tests, which showed the clearance of cervical HPV strains and the warts' disappearance. 27 patients (29.3%) registered the persistence of HPV cervical strains initially diagnosed while in 31 cases (33.7%) the treatment was partially effective leading to the disappearance of some of the HPV strains detected. Two of these 27 patients were subsequently diagnosed with highgrade cervical dysplasia that required trachelectomy. The distribution of the HPV positive cases is showed in Table III . A statistical improvement after EBT was identified in the case of HPV6, HPV42, HPV 59 and HPV84 (Table III) . At the end of our study, the satisfaction questionnaire filled by all patients recorded moderate dissatisfaction for 20 patients (21.7%) when talking about the routine of administrating the medication (three tablets three times per day) and high dissatisfaction for 4 patients (4.3%) concerning the duration of treatment (six months). EBT was perceived as effective by 43.5%
of the patients and 91.4% of the patients considered that EBT is safe (Table IV) . The persistent HPV infection, particularly with highrisk HPV strains is considered to be a premise for the development of pre-malignant cervical lesions and cervical cancer [10, 11] . The identification of HPV as an etiological factor for malignancies creates the opportunity for the control of these cancers through immunization and other targeted therapies [12] . The persistent infection with HPV is defined as having two or more HPV tests positive [13] , though the length of the time period to define the persistent infection is still under debate [13, 14] . Thuja occidentalis, one of the components of EBT, origins from North America. Only the dried twig tips of the species Thuja occ. are used in the extract. A critical factor for Thuja's use as a medicinal herb is its content of essential oil that can represent 1.4 -4% of the dried substances. The method of extraction for this oil is also of great importance, alcoholic extracts having a higher content of thujone (main essential oil found in Thuja) than water extracts. The essential oil of the leaves is not the only one investigated for its biological activity -high molecular weight glycoproteins/ polysaccharides are also credited for having in vitro biological functions [8] . Studies concerning another EBT component, Baptisia tinctoria, proved the antibacterial, antiviral and anti-inflammatory effects of this plant [15, 16] . The strength of our study is represented by the use of this particular herbal mixture with antiviral properties -EBT-in the cervical HPV infection (its effects upon immunity being already demonstrated in respiratory viral or bacterial infections) [8, 17] . Surveilling the literature did not provide any information concerning the use of our investigational product in the treatment of cervical HPV infection, although studies regarding the use of EBT as adjuvant in HIV or hepatitis B infection have been published [8, 18] . Several studies conducted mainly in Germany have investigated the effects of EBT's components on immunity. They showed that the mixture of plants found in this product has non-specific immunomodulatory properties (activation of macrophages, differentiation of B lymphocytes with immunoglobulins' synthesis increase, activation of CD4-positive cells, stimulation of splenic cells proliferation, increase of nitric oxide (NO) production in alveolar macrophages, direct viral replication and growth inhibition), thus acting as an antigen-independent, positive influence on the immunoprotective mechanisms of the organism [7, 8, 15, 16, 19] . The immunopharmacological potential has been investigated on in vitro and in vivo test models [8] .
To our knowledge, our observational study is the first study developed using EBT for the treatment of cervical HPV infection. The percentage of patients who had good response after using EBT for cervical HPV infection (63.0%) is not enough to draw a definitive conclusion, so the use of this investigational product for cervical HPV infection deserves further investigation (higher numbers of patients included in the study, randomized clinical trials).
Conclusions
The treatment of cervical HPV infection is mainly oriented towards the cure of cervical HPV induced lesions rather than the eradication of the HPV infection. Drugs such as EBT are acting as immunomodulators, helping the host to fight against the pathogenic agent and thus preventing the occurrence of cervical cancer. Further studies are needed for this investigational product to be proven efficient as antiviral therapy in HPV infection.
